Clinical evaluation of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis: Efficacy, safety, patient experience and adherence

Medicine & Life Sciences

• Dimethyl Fumarate 100%
• Relapsing-Remitting Multiple Sclerosis 79%
• Patient Compliance 62%
• Safety 37%
• Patient Reported Outcome Measures 28%
• Patient Outcome Assessment 19%
• Progressive Multifocal Leukoencephalopathy 17%
• Mouth Diseases 15%
• Phase III Clinical Trials 15%
• Efficiency 13%
• Patient Satisfaction 11%
• Aspirin 11%
• Compliance 11%
• Multiple Sclerosis 11%
• Counseling 10%
• Risk Assessment 10%
• Therapeutics 10%
• Placebos 8%
• Quality of Life 8%
• Liver 6%
• Incidence 6%
• Pharmaceutical Preparations 5%

Social Sciences

• multiple sclerosis 85%
• evaluation 29%
• adverse events 28%
• stabilization 23%
• Clinical Trials 22%
• experience 19%
• tolerance 19%
• incidence 18%
• productivity 17%
• quality of life 17%
• counseling 17%
• monitoring 15%
• drug 14%
• cause 12%
• management 10%
• health 9%
• evidence 8%
• literature 8%